Transformation from lung adenocarcinoma to combined small cell carcinoma in pleural effusion after treatment with osimertinib

The transformation of lung adenocarcinoma to combined small cell lung cancer is a rare mechanism of acquired resistance to EGFR tyrosine kinase inhibitors. This case describes this mechanism in a pleural effusion of a young patient treated with osimertinib for 18 months.

Detalles Bibliográficos
Autores principales: Frankel, Diane, Kaspi, Elise, Liprandi, Agnès, Dales, Jean‐Philippe, Roll, Patrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544831/
https://www.ncbi.nlm.nih.gov/pubmed/35689552
http://dx.doi.org/10.1111/cyt.13156
Descripción
Sumario:The transformation of lung adenocarcinoma to combined small cell lung cancer is a rare mechanism of acquired resistance to EGFR tyrosine kinase inhibitors. This case describes this mechanism in a pleural effusion of a young patient treated with osimertinib for 18 months.

Ejemplares similares